The Importance of a Regulatory Submission Content Planner

A BLA Regulatory Content Plan is one of the most important project management tools for your critical regulatory submission. It serves as the master roadmap that identifies every document required for the BLA, assigns ownership, tracks dependencies, and establishes timelines for authoring, review, quality control, publishing, and submission.

Without a content plan, sponsors risk discovering critical gaps late in development, which can delay filing, increase costs, and potentially lead to FDA filing issues. For emerging biotech companies, a content plan provides visibility into the significant volume of documentation required across Clinical, Nonclinical, CMC, Regulatory, and Administrative functions

What does a Content Planner for a practical Biological Licensing Application (BLA) typically include?

• Document Inventory- Master list of all required documents and version control details

• Responsibility Matrix- Author, reviewer, approver assignments

• Gap Assessment- Identifies missing studies or reports

• Timeline- Draft, review, QC, and finalization dates

• Dependency Map- Tracks documents dependent on other deliverables

• Publishing Schedule- Submission assembly and validation milestones

Documents to include according to the BLA eCTD Module

Module 1: Administrative Information

• FDA Forms (e.g., Form 356h)

• Cover Letter

• User Fee Cover Sheet

• Debarment Certification

• Financial Disclosure Forms

• Patent Information

• Labeling Documents

• REMS (if applicable)

• Environmental Assessment or Claim of Categorical Exclusion

• Field Copy Certification (if applicable)

Module 2: Summaries and Overviews

• Quality Overall Summary (QOS)

• Nonclinical Overview

• Clinical Overview

• Nonclinical Written and Tabulated Summaries

• Clinical Summary

These documents are often among the most resource-intensive because they integrate information from all other modules.

Module 3: Quality (CMC)

For biologics, Module 3 is frequently the largest and most complex section.

Key documents include:

• Drug Substance Information

• Drug Product Information

• Manufacturing Process Descriptions

• Control of Materials

• Process Validation Reports

• Analytical Method Validation Reports

• Specifications and Justifications

• Stability Reports

• Container Closure Information

• Comparability Studies

• Reference Standards Documentation

• Adventitious Agent Safety Assessments

  
  

Module 4: Nonclinical Study Reports

• Pharmacology Reports

• Toxicology Reports

• Pharmacokinetic Studies

• Biodistribution Studies (for certain biologics and gene therapies)

• Immunogenicity Assessments

• Study Protocols and Reports

  
  

Module 5: Clinical Study Reports

• Clinical Study Reports (CSRs)

• Integrated Summary of Safety (ISS)

• Integrated Summary of Efficacy (ISE)

• Clinical Protocols and Amendments

• Statistical Analysis Plans

• Patient Narratives

• Case Report Forms (selected)

• Clinical Datasets and Define Files

• Pharmacovigilance Information

What is the recommended BLA content planning timeline?

A content plan should ideally be established 18–24 months before the planned BLA submission date and maintained as a living document throughout development. This approach significantly reduces the risk of a Refuse-to-File (RTF) action during FDA's 60-day filing review.

Time Before Submission	Key Activities
24–18 months	Create the initial content plan, document inventory, responsibility matrix, and gap assessment. Identify all Module 2–5 deliverables and major CMC reports.
18–12 months	Confirm author assignments, develop document templates, establish review workflows, and begin drafting foundational CMC and summary documents.
12–9 months	Finalize study report schedules, begin drafting Module 2 summaries, identify any documentation gaps, and confirm datasets and standards.
9–6 months	Complete most Clinical Study Reports (CSRs), nonclinical reports, and major CMC reports. Start integrated summaries and quality reviews.
6–3 months	Finalize Module 2 documents, labeling drafts, administrative forms, and quality control reviews. Begin eCTD publishing readiness activities.
3–1 month	Final document approvals, hyperlinking, publishing, validation, and submission readiness reviews.
Submission Date	Submit the BLA through the Electronic Submissions Gateway (ESG).

To summarize, BLA (Biologics License Application) content plan is more than a list of submission documents—it is a roadmap that identifies every document, owner, dependency, and timeline required to assemble a complete BLA, and it is critical for ensuring everyone is aligned in expectations. Developing the content plan early helps sponsors identify gaps, allocate resources, and prepare for FDA review well before the filing date.

Pro-Tip: Online AI tools have become a great resource for generating a starting content planner; however, do not rely on the tool solely. Consider using it as a first draft only. It is critical to check it against updated resources and guidelines, as well as your specific commitments and meeting minutes, as discussed and agreed with the Agencies. Relying on an AI tool without double-checking the content introduces the risk of leaving out pertinent information or adding unnecessary information, and wasting time.

Online tools like Smartsheet can also be a great way to keep an updated content planner visible to your cross-functional teams. But we also think that having a robust Excel spreadsheet also does the job with the right permissions, team access, and controls in place.

Contact SWOT at info@sugarwaterops.com for additional questions regarding ways to create and/or use a Submission Content Planner to get the most out of it.